N
17.55
-0.65 (-3.57%)
| Previous Close | 18.20 |
| Open | 17.66 |
| Volume | 1,352,086 |
| Avg. Volume (3M) | 1,060,347 |
| Market Cap | 1,956,579,200 |
| Price / Sales | 3.18 |
| Price / Book | 5.61 |
| 52 Weeks Range | |
| Earnings Date | 24 Apr 2025 |
| Profit Margin | -26.41% |
| Operating Margin (TTM) | -24.43% |
| Diluted EPS (TTM) | -1.51 |
| Quarterly Revenue Growth (YOY) | 11.90% |
| Total Debt/Equity (MRQ) | 192.49% |
| Current Ratio (MRQ) | 1.47 |
| Operating Cash Flow (TTM) | -30.46 M |
| Levered Free Cash Flow (TTM) | 16.94 M |
| Return on Assets (TTM) | -8.64% |
| Return on Equity (TTM) | -45.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | NovoCure Limited | Bearish | Mixed |
AIStockmoo Score
-0.3
| Analyst Consensus | 1.0 |
| Insider Activity | 0.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.30 |
|
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 9.87% |
| % Held by Institutions | 87.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (Piper Sandler, 93.73%) | Buy |
| Median | 28.00 (59.54%) | |
| Low | 27.00 (Wedbush, 53.85%) | Hold |
| Average | 29.67 (69.06%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 16.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 23 Apr 2025 | 34.00 (93.73%) | Buy | 17.77 |
| Wedbush | 16 Apr 2025 | 27.00 (53.85%) | Hold | 15.83 |
| JP Morgan | 10 Apr 2025 | 28.00 (59.54%) | Hold | 16.08 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HILLEMAN JERYL L | 16.72 | 17.04 | 10,216 | 170,492 |
| HUNG DAVID | 16.72 | 17.04 | 10,216 | 170,492 |
| LEONARD FRANK X | 16.72 | - | 179,426 | 3,000,003 |
| LEUNG GABRIEL | 16.72 | 17.04 | 10,216 | 170,492 |
| MADDEN MARTIN J. | - | 17.04 | -999 | -17,023 |
| OCEAN ALLYSON J | 16.72 | 17.04 | 10,216 | 170,492 |
| SCANNELL TIMOTHY J | 16.72 | 17.04 | 10,216 | 170,492 |
| STAFFORD KRISTIN | 16.72 | 17.04 | 10,216 | 170,492 |
| VERNON W ANTHONY | 16.72 | 17.04 | 10,216 | 170,492 |
| Aggregate Net Quantity | 249,939 | |||
| Aggregate Net Value ($) | 4,176,423 | |||
| Aggregate Avg. Buy ($) | 16.72 | |||
| Aggregate Avg. Sell ($) | 17.04 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LEONARD FRANK X | Officer | 04 Jun 2025 | Acquired (+) | 179,426 | 16.72 | 3,000,003 |
| VERNON W ANTHONY | Director | 04 Jun 2025 | Acquired (+) | 11,215 | 16.72 | 187,515 |
| HUNG DAVID | Director | 04 Jun 2025 | Acquired (+) | 11,215 | 16.72 | 187,515 |
| SCANNELL TIMOTHY J | Director | 04 Jun 2025 | Acquired (+) | 11,215 | 16.72 | 187,515 |
| OCEAN ALLYSON J | Director | 04 Jun 2025 | Acquired (+) | 11,215 | 16.72 | 187,515 |
| HILLEMAN JERYL L | Director | 04 Jun 2025 | Acquired (+) | 11,215 | 16.72 | 187,515 |
| STAFFORD KRISTIN | Director | 04 Jun 2025 | Acquired (+) | 11,215 | 16.72 | 187,515 |
| LEUNG GABRIEL | Director | 04 Jun 2025 | Acquired (+) | 11,215 | 16.72 | 187,515 |
| HUNG DAVID | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| VERNON W ANTHONY | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| OCEAN ALLYSON J | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| HILLEMAN JERYL L | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| SCANNELL TIMOTHY J | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| MADDEN MARTIN J. | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| LEUNG GABRIEL | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| STAFFORD KRISTIN | Director | 03 Jun 2025 | Sell (-) | 999 | 17.04 | 17,023 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 31 May 2025 | Announcement | Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting |
| 24 Apr 2025 | Announcement | Novocure Reports First Quarter 2025 Financial Results |
| 23 Apr 2025 | Announcement | Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting |
| 22 Apr 2025 | Announcement | Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer |
| 01 Apr 2025 | Announcement | Novocure to Report First Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |